Blueprint Medicines Corporation
BPMC · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -28.02 | 2.47 | -2.32 | 0.22 |
| FCF Yield | -1.00% | -0.55% | -0.23% | -0.74% |
| EV / EBITDA | -137.02 | -218.12 | -187.12 | -256.08 |
| Quality | ||||
| ROIC | -1.58% | -4.28% | -4.92% | -3.97% |
| Gross Margin | 98.12% | 94.91% | 98.49% | 91.89% |
| Cash Conversion Ratio | -109.84 | 0.59 | 0.24 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | 40.06% | 35.61% | 16.85% | 16.32% |
| Free Cash Flow Growth | -85.87% | -121.75% | 73.02% | 50.65% |
| Safety | ||||
| Net Debt / EBITDA | -0.01 | -13.54 | -11.45 | -23.26 |
| Interest Coverage | -5.05 | -2.27 | -2.61 | -2.56 |
| Efficiency | ||||
| Inventory Turnover | 0.22 | 0.55 | 0.15 | 0.76 |
| Cash Conversion Cycle | 438.42 | 130.16 | 410.12 | 135.14 |